PAOG Confirms Farmersville Hemp Brand CBD Product Line Development For PURA
Sandusky, OH, Jan. 06, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today confirmed the development of a line of CBD nutraceutical products for Puration, Inc. (OTC Pink: PURA) is underway.
PURA has updated its business model over the course of the last year and is now focusing on the development of a hemp business cooperative under the brand name Farmersville Hemp.
PURA has established its new business model to build an industrial hemp business with 3 sources of revenue – education, branding and partnerships.
PURA recently announced signing its first Farmersville Hemp clients that will in turn contribute to the company’s 2022 revenue objectives.
Last year, PAOG acquired intellectual property derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960).
PAOG is developing both pharmaceutical and nutraceutical treatments for humans based on this intellectual property.
PAOG and PURA are partnering on the development of CBD infused products to be marketed under the Farmersville Hemp brand name. Look for details on the Farmersville CBD products to be announced later this month.
PAOG currently markets its own independent line of CBD nutraceutical products under its “RX” label available for sale on North American Cannabis Inc.’s (OTC Pink: USMJ) ecommerce site www.usmj.com.
For more information on Puration, visit http://www.purationinc.com
Learn more about PAOG at www.paogroupinc.com.
This News Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from any these statements. You are cautioned not to place undue reliance on any those forward-looking statements. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements after the date of this news release. None of such forward-looking statements should be regarded as a representation by us or any other person that the objectives and plans set forth in this News Release will be achieved or be executed.
For More Information Contact:
Upcoming Life Sciences Events
- August 2022
- Biotechgate Digital Partnering August 2022
- September 2022
- Redefining Early Stage Investments (RESI)
- BioPharm America™ 2022